Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2578826 | Thérapie | 2014 | 6 Pages |
Abstract
Despite very different aetiologies and clinical expressions, advancing knowledge in the physiopathology and treatment of immune and inflammatory diseases (IID) prompts us to consider them as a whole. These are chronic, often incapacitating and painful illnesses that progress and destroy organs. Management by discipline too often leads to erroneous diagnoses and sometimes inappropriate treatment. More integrated translational research would further understanding of the complex relationships between cytokines and organ damage, which vary with the conditions and patients, making it possible to develop new biomarkers and personalize treatment. The research in France has very many strengths but its organization is fragmented. Better coordinated research into IID, which could be based on creating a strategic valorization field (domaine de valorisation stratégique, DVS) and thematic multi-organization institute (Institut thématique multi-organismes ITMO), would advance patient management.
Keywords
ANRCSISCVTIL-17GIMIIDCICCRBDHUPHRCTNFDVSAVIESANDGOSSATTDNAPK/PDArthritisdeoxyribonucleic acidinflammationinterleukin-17Autoimmune diseasesinflammatory bowel diseasesTranslational medical researchtumour necrosis factor-alphamicro ribonucleic acidPharmacokinetic/pharmacodynamicVascular Endothelial Growth Factor (VEGF)MicroRNA
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology, Toxicology and Pharmaceutics (General)
Authors
Jean-Michel Joubert, Jacques-Eric Gottenberg, Gilles Paintaud, participants of round table N° 2 of Giens XXIX participants of round table N° 2 of Giens XXIX, Béatrice Augendre-Ferrante, Christophe Cans, Dominique Cellier, Marie-Pierre Chevalier,